Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases. The company, with the help of its virus-like particle (VLP) platform technology, focuses primarily on life-threatening respiratory diseases. Its products in pipeline include IVX-A12, an respiratory syncytial virus (RSV) monovalent antigen candidate with RSV/human metapneumovirus (hMPV) bivalent target indication; IVX-121, a vaccine candidate with RSV target; IVX-241, a vaccine candidate with hMPV target; IVX-411, an original receptor binding domain (RBD) sequence antigen with SARS-CoV-2^ target indication; and IVX-421, a variant RBD antigen with SARS-CoV-2^ target indication. The company was incorporated in 2017 and is headquartered in Seattle, Washington.